COMP <GO>
SUPN vs NAMS // 10Y YIELD & FRED MACRO BETA
Supernus Pharmaceuticals Inc. (NASDAQ) VS. NewAmsterdam Pharma Company N.V. (NASDAQ) • 15-METRIC TALLY: SUPN 7
— NAMS 2
■ METRIC PARITY
LAST: $41.84 (+1.85%) • MKT CAP: $2.43B
macro-sensitivity
0.88
LAST: $20.76 (-1.47%) • MKT CAP: $2.48B
macro-sensitivity
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SUPN VS. NAMS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SUPN | NAMS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 89.60% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -4.50% | -35.00% | +30.50 | SUPN | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.89% | -5.96% | +7.85 | SUPN | /fcf-yield <GO> |
| Operating Margin | -8.70% | -60.00% | +51.30 | SUPN | /operating-margins <GO> |
| Net Profit Margin | -5.40% | -60.00% | +54.60 | SUPN | /net-margins <GO> |
| Revenue Growth (YoY) | 8.60% | -50.60% | +59.20 | SUPN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.84 | 15.94 | -11.10 | NAMS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 3/9 | +4.00 | SUPN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.5 | 45.6 | +4.90 | SUPN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 0.88 | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.0x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.43B | $2.48B | -$49.6M | NAMS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SUPN REV | NAMS REV | SUPN GROSS % | NAMS GROSS % | SUPN FCF | NAMS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $719.0M | $22.5M | 89.6% | — | $46.0M | -$147.8M |
| FY 2024 | $661.8M | $45.6M | 88.2% | — | $171.2M | -$158.6M |
| FY 2023 | $607.5M | $14.1M | — | — | $83.7M | -$141.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SUPN // BETA 0.88
NAMS // BETA —